Hepatitis B virus genotype B is associated with better response to thymosin α1 therapy than genotype C

Journal of Viral Hepatitis

Volumn 13, Issue 12, 2006, Pages 845-850

  Chien, R N ^a,b   Lin, C Y ^a   Yeh, C T ^a   Liaw, Y F ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Complete response; Core promoter mutation; Genotype; Hepatitis B virus; Precore stop codon mutation; Thymosin 1 therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; THYMOSIN ALPHA1; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; STOP CODON; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; FEMALE; GENOTYPE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MUTATION; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; THYMOSIN; TREATMENT OUTCOME;

EID: 33751016826     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00761.x     Document Type: Article

References (45)

1. Carman W, Thomas HC, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993; 341: 349-353.
2. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
3. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-2583.
4. Stuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81: 67-74.
5. Mayerat C, Mantegani A, Frel PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6: 299-304.
6. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-2073.
7. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlated with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
8. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 1207-1209.
9. Chu CJ, Lak AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35: 1274-1276.
10. Ni YH, Chang MH, Wang KJ et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127: 1733-1738.
11. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B. J Hepatol 2005; 43: 411-417.
12. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotype and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
13. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430.
14. Erhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-725.
15. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8-16.
16. Janssen HL, van Zonneveld M, Senturk H et al. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients. Lancet 2005; 365: 123-129.
17. Kao JH, Liu CJ, Chen DS. Hepatitis genotypes and lamivudine resistance. J Hepatol 2002; 36: 303-304.
18. Yuen MF, Wong DK, Sablon E et al. Hepatitis B virus genotype B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8: 531-534.
19. Chien RN, Liaw YF. Short term lamivudine therapy in patients with chronic hepatitis B. Intervirology 2003; 46: 363-366.
20. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005; 43: 72-77.
21. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-1273.
22. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-438.
23. Westland C, Delaney WT, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125: 107-116.
24. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci U S A 1986; 83: 6107-6111.
25. Serrate SA, Schulof RS, Leonidas L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 1987; 139: 2338-2343.
26. Baxavanis CN, Recios GJ, Perez S, Kokkinopoulos D, Papamichail M. Immunoregulatory effects of fraction 5 thymus peptide-thymosin α1 enhances while thymosin β4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. Immunopharmacology 1987; 13: 133-141.
27. Andreone P, Cursaro C, Gramenzi A et al. In vitro effect of thymosin-alpha 1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 194-201.
28. Mutchnick MG, Appelman HD, Chung HT et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991; 14: 409-415.
29. Andreone P, Cursaro C, Gramenzi A et al. A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-777.
30. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin-α1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27: 1383-1387.
31. Mutchnick MG, Lindsay KL, Schiff ER et al. Thymosin-α1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6: 397-403.
32. You J, Zhuang L, Tang BZ et al. A randomized controlled clinical trial on the treatment of thymosin-α1 versus interferon-α in patients with hepatitis B. World J Gastroenterol 2001; 7: 411-414.
33. Zavaglia C, Severini R, Tinelli C et al. A randomized, controlled study of thymosin-α1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000; 45: 690-696.
34. Zhuang L, You J, Zhang B et al. Preliminary results of thymosin-α1 versus interferon-α treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001; 7: 407-410.
35. Kuhns MC, McNamara AL, Perrillo RP, Cabal CM, Campbell CR. Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Virol 1989; 27: 274-281.
36. Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infection in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815-1818.
37. Suzuki F, Suzuki Y, Tsubota A et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002; 37: 824-830.
38. Sugauchi F, Orito E, Ichida T et al. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-5992.
39. Sagauchi F, Orito E, Ichida T et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124: 925-932.
40. Jazayeri M, Basuni AA, Sten N et al. HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat 2004; 11: 488-501.
41. Matloubian N, Somasundaram T, Kolhekar SR, Selvakumar R, Ahmed R. Genetic basis of viral persistence: single amino acid changes in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J Exp Med 1990; 172: 1043-1048.
42. Wherry EJ, Blattman JN, Mural-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-4927.
43. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-1044.
44. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976-984.
45. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782.